A new study published in Vaccine found that HPV vaccination for girls is highly cost-effective in Kenya, and that a single-dose strategy could have similar benefits for less cost.
Researchers used a proportionate outcomes static cohort model to evaluate the annual budget impact and lifetime cost-effectiveness of vaccinating ten-year-old girls over the period 2020–2029, including a catch-up campaign for girls aged 11–14 years in 2020. The study estimated the potential cost-effectiveness of four different vaccines (CERVARIX, CECOLIN, GARDASIL-4, and GARDASIL-9), one of which was introduced in Kenya in 2019 (GARDASIL-4), comparing each product to no vaccination and to each other.
Compared to GARDASIL-4, alternative products could provide similar or greater health benefits at lower net costs. Substantial government funding will be required to reach and sustain coverage targets as Kenya graduates from Gavi support.
Any organization or individual working in the field of immunization economics can submit findings, opportunities, calls to action, or other relevant work below to be shared with our community.